Orai3 calcium channel and resistance to chemotherapy in breast cancer cells: the p53 connection

被引:0
|
作者
Jessy Hasna
Frédéric Hague
Lise Rodat-Despoix
Dirk Geerts
Catherine Leroy
David Tulasne
Halima Ouadid-Ahidouch
Philippe Kischel
机构
[1] Université de Picardie Jules Verne,Department of Medical Biology L2
[2] UFR des Sciences,109
[3] Laboratoire de Physiologie Cellulaire et Moléculaire (EA 4667),undefined
[4] SFR CAP-SANTE (FED 4231),undefined
[5] Academic Medical Center—University of Amsterdam,undefined
[6] Equipe Signalisation,undefined
[7] Apoptose et Cancer CNRS UMR8161,undefined
[8] Institut de Biologie de Lille - Institut Pasteur,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Orai proteins are highly selective calcium channels playing an important role in calcium entry. Orai3 channels are overexpressed in breast cancer (BC) tissues, and involved in their proliferation, cell cycle progression and survival. Herein, we sought to address the involvement of Orai3 in resistance to chemotherapeutic drugs. Using high-throughput approaches, we investigated major changes induced by Orai3 overexpression, including downstream signaling mechanisms involved in BC chemotherapy resistance. Resistance was dependent on external calcium presence and thus Orai3 functionality. This effect allowed a downregulation of the p53 tumor suppressor protein expression via the pro-survival PI3K/Sgk-1/Sek-1 pathway. We demonstrated that p53 degradation occurred not only via Mdm2, but also via another unexpected E3 ubiquitin ligase, Nedd4-2. We found supporting bioinformatic evidence linking Orai3 overexpression and chemoresistance in large human BC data sets. Altogether, our results shed light on the molecular mechanisms activated in BC cells commonly found to overexpress Orai3, allowing resistance to chemotherapeutic drugs.
引用
收藏
页码:693 / 707
页数:14
相关论文
共 50 条
  • [31] Is p53 a breast cancer gene?
    Polyak, K
    CANCER BIOLOGY & THERAPY, 2002, 1 (01) : 37 - 38
  • [32] P53 and breast cancer, an update
    Lacroix, Marc
    Toillon, Robert-Alain
    Leclercq, Guy
    ENDOCRINE-RELATED CANCER, 2006, 13 (02) : 293 - 325
  • [33] The p53 pathway in breast cancer
    Milena Gasco
    Shukri Shami
    Tim Crook
    Breast Cancer Research, 4
  • [34] P53 AND BREAST CANCER SUBTYPES
    Bertheau, P.
    Lehmann-Che, J.
    Varna, M.
    Dumay, A.
    Poirot, B.
    Turpin, E.
    Plassa, L.
    De Cremoux, P.
    Janin, A.
    Giacchetti, S.
    Espie, M.
    De The, H.
    BREAST, 2013, 22 : S4 - S4
  • [35] The p53 pathway in breast cancer
    Gasco, M
    Shami, S
    Crook, T
    BREAST CANCER RESEARCH, 2002, 4 (02) : 70 - 76
  • [36] P53, Apoptosis, and Breast Cancer
    Barnes, Diana M.
    Camplejohn, Richard S.
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1996, 1 (02) : 163 - 175
  • [37] Down-Regulation of Orai3 Arrests Cell-Cycle Progression and Induces Apoptosis in Breast Cancer Cells But Not in Normal Breast Epithelial Cells
    Faouzi, Malika
    Hague, Frederic
    Potier, Marie
    Ahidouch, Ahmed
    Sevestre, Henri
    Ouadid-Ahidouch, Halima
    JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (02) : 542 - 551
  • [38] Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells
    Bouard, Louise
    Tessoulin, Benoit
    Descamps, Geraldine
    Touzeau, Cyrille
    Moreau, Philippe
    Amiot, Martine
    Pellat-Deceunynck, Catherine
    BLOOD, 2019, 134
  • [39] Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?
    Armelle Degeorges
    Anne de Roquancourt
    Jean Marc Extra
    Marc Espie
    Edwige Bourstyn
    Patricia de Cremoux
    Thierry Soussi
    Michel Marty
    Breast Cancer Research and Treatment, 1998, 47 : 47 - 55
  • [40] p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer
    Dublin, EA
    Miles, DW
    Rubens, RD
    Smith, P
    Barnes, DM
    INTERNATIONAL JOURNAL OF CANCER, 1997, 74 (06) : 605 - 608